Patents by Inventor Michael R. Myers

Michael R. Myers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230105060
    Abstract: A bottle opener having the shape of a human hand provides a handle and cap gripping component which is configured for removing a conventional bottle cap in a compressed fit upon a bottle. The configuration provides cap removal in a direction toward the user with less effort. The cap gripping component can be configured to removably engage the handle where a tool such as a golf divot tool can be stored within an interior of the handle.
    Type: Application
    Filed: October 1, 2021
    Publication date: April 6, 2023
    Inventors: Emilie Myers, Michael R. Myers
  • Patent number: 8606418
    Abstract: A control system is provided. The control system comprises an electronic processor configured to control operation of at least one wind turbine. The control system further comprises at least one weather radar unit positioned proximate to the at least one wind turbine and configured to generate weather data. The electronic processor is configured to control the operation of the at least one wind turbine based on the weather data generated by the at least one weather radar unit.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: December 10, 2013
    Assignee: Rockwell Collins, Inc.
    Inventors: Michael R. Myers, Joseph J. Engler
  • Patent number: 7946010
    Abstract: A tool for installing irrigation barb emitters into irrigation tubing including a cradle handle and a punch handle, the cradle handle and the punch handle being arranged in a parallel relation and connected intermediate their ends at a center point. A cradle which receives irrigation tubing is included. A punch pin allows a user to punch holes in irrigation tubing as desired with a spring loaded body which removes the punch pin when it has been driven into irrigation tubing. A barb holder allows a user to install emitter barbs into irrigation tubing as desired. A barb remover allows removal of barbs from irrigation tubing as desired.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: May 24, 2011
    Assignee: EMC Industries LLC
    Inventors: Michael R. Myers, Stephanie DePascal
  • Patent number: 7741316
    Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: June 22, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Patent number: 7612075
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 3, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Michael R. Myers, Wan F. Lau, Aiwen Li, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Patent number: 7550597
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: June 23, 2009
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
  • Patent number: 7265111
    Abstract: The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are independently 0, 1, 2, or 3, provided that n+p is a least 1; and unsubstituted and at least monosubstituted C1-C10-alkylene-Y, C2-C10-alkylene-Y, C3-C10-cycloalkylene-Y and C3-C10-cycloalkenylene-Y; and R1, A, B, Q, T, Y, E and W have the meanings given in the description. These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: September 4, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Antony Bigot, Siegfried Stengelin, Gerhard Jaehne, Andreas Herling, Guenter Mueller, Franz Jakob Hock, Michael R Myers
  • Patent number: 7132414
    Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH?CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: November 7, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Patent number: 6872717
    Abstract: A method of treating or preventing obesity, this method comprising administering to a patient in need of such treatment an effective amount of a compound of formula in which R, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: March 29, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Patent number: 6852712
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: February 8, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Patent number: 6846815
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: January 25, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
  • Patent number: 6821962
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: November 23, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Publication number: 20040157823
    Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: 1
    Type: Application
    Filed: February 4, 2004
    Publication date: August 12, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Publication number: 20040127434
    Abstract: The present invention relates to compounds according to the general formula (I) 1
    Type: Application
    Filed: June 27, 2003
    Publication date: July 1, 2004
    Inventors: Antony Bigot, Siegfried Stengelin, Gerhard Jaehne, Andreas Herling, Guenter Mueller, Franz Jakob Hock, Michael R. Myers
  • Publication number: 20040102450
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
    Type: Application
    Filed: July 25, 2003
    Publication date: May 27, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Aiwen Li, Michael R. Myers, Wan F. Lau, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Patent number: 6734176
    Abstract: The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which R1 represents a radical —NHCOR4 or —N(R5)—Y—R6, Y is CO or SO2, R4 represents a radical -alk-SO2—R11, -alk-SO2—CH═CH—R11 or Het substituted with —SO2—R11 or a phenyl radical substituted with —SO2—R11 or -alk-SO2—R11, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: May 11, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Patent number: 6696434
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: February 24, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Publication number: 20040014774
    Abstract: This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.
    Type: Application
    Filed: July 10, 2003
    Publication date: January 22, 2004
    Inventors: Michael R. Myers, Alfred P. Spada, Martin P. Maguire, Paul E. Persons, Asher Zilberstein, Chin-Yi Jenny Hsu, Susan E. Johnson
  • Patent number: 6645969
    Abstract: This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 11, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Martin P. Maguire, Paul E. Persons, Asher Zilberstein, Chin-Yi Jenny Hsu, Susan E. Johnson
  • Publication number: 20030176390
    Abstract: This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.
    Type: Application
    Filed: May 14, 2002
    Publication date: September 18, 2003
    Inventors: Andreas Herling, Gerhard Jaehne, Martin P. Maguire, Alfred P. Spada, Michael R. Myers, Yong Mi Choi-Sledeski, Heinz W. Pauls, William R. Ewing